Mar 04, 2020 (Heraldkeepers) -- Overactive bladder is a common medical condition, in which there arises a sudden urge for urination at any time. Overactive bladder is sometimes coupled with urine leakage, which is a condition called urinary incontinence. Millions of people across the globe suffer from overactive bladder and it is more common among the older generation. Urine leakage and frequent urination are the main symptoms of overactive bladder . The frequency of urination in the patient is more than eight times a day. Moreover, frequent urination during sleep hours is common in such patients. Overactive bladder is generally diagnosed through tests, such as urine culture, bladder scan, cystoscopy, or urodynamic testing.
A robust drug pipeline of drugs, which are undergoing phase II and phase III clinical trials, is soon expected to be available across the market, and this is expected to drive the global overactive bladder treatment market growth. However, alternate therapies, such as the neuromodulation therapy, which includes sacral neuromodulation and percutaneous tibial nerve stimulation to deliver electric impulse to nerve, are projected to hinder the global market growth.
Download PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2007
Global Overactive Bladder Treatment Market Dynamics
High prevalence of overactive bladder is expected to propel the global overactive bladder treatment market growth over the forecast period. Moreover, escalating awareness about the importance of diagnosis and treatment of the disease is a key factor leading to an increased number of patients being treated for the condition. Furthermore, increasing number of drug development programs for overactive bladder is expected to fuel the overactive bladder treatment market growth, by adding new drug in the market. Currently, generic drugs, such as cholinergic receptor inhibitors, are available for the treatment of this condition. Therefore, development and approval of new drug entity with a better drug profile, are likely to boost the global market growth.
For instance, in 2018, Urovant Sciences, a biopharmaceutical company that focuses on developing novel therapies for urologic conditions, entered the phase III clinical trial for its drug 'Vibegron', which is an oral Beta-andrenergic agonist indicated for the overactive bladder treatment. Furthermore, Taris Biomedical LLC entered the phase II clinical trials for its drug candidate TAR-302 for the treatment of overactive bladder. TAR 302 is a trospium chloride-based continuous local therapy, which is expected to efficiently aid in the treatment of overactive bladder, with just a few side effects.
The key players operating in the global overactive bladder treatment market are focused on the development of a wide range of combinational therapies. For instance, in 2017, Astellas Pharma, Inc. received supplemental New Drug Application (sNDA) from FDA for conditional therapy of mirabegron and solifenacin succinate for the treatment of urinary incontinence.
Global Overactive Bladder Treatment Market – Regional Analysis
The North America overactive bladder treatment market holds a dominant position, owing to the high prevalence of overactive bladder across the region. According to the 2016 review published in the journal Current Bladder Dysfunction Reports, millions of people suffer from overactive bladder in the U.S. each year and there has been a continuous increase in the cost of overactive bladder treatments over the recent years. However, surging awareness about the disease in Asia Pacific regions is expected to boost the overactive bladder treatment market growth in the region in the upcoming years.
Purchase this Report @ Price 4500 USD for Single-User License: https://www.coherentmarketinsights.com/insight/buy-now/2007
Global Overactive Bladder Treatment Market - Competitive Analysis
The key players operating in the global overactive bladder treatment market include Janssen Pharmaceuticals Inc., Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Barr Laboratories Inc. (a subsidiary of Teva Pharmaceuticals), Alembic Pharmaceuticals Ltd., Pfizer Inc., Astellas Pharma Inc., Endo International PLC, and Invagen Pharmaceuticals Inc.
These players have been focusing on leveraging their expertise to develop novel treatment therapies for the disease. For instance, in 2017, UroGen Pharma Ltd., a clinical-stage biopharmaceutical company, in collaboration with Allergan Pharmaceuticals International Limited, entered into the phase II clinical trial for RTGel, in combination with BOTOX, for the overactive bladder treatment. RTGel is a hydrogel-based proprietary formulation of UroGen Pharma Ltd.
On the basis of drug type: